Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Blood

• Publication date

  2010-05-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2009-11-255620PMID 20124509PMCID PMC2879104
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3

  2009cited by this paper
• Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.

  2009cited by this paper
• Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

  2009cited by this paper
• Changes in the Expression of Proteasome Genes in Tumor Cells Following Short-Term Proteasome Inhibitor Therapy Predicts Survival in Multiple Myeloma Treated with Bortezomib-Containing Multi-Agent Chemotherapy

  2008cited by this paper
• An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.

  2008influential reference
• Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2

  2008cited by this paper
• High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.

  2007cited by this paper
• International uniform response criteria for multiple myeloma

  2007cited by this paper
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only.

  2007cited by this paper
• Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

  2007cited by this paper
• Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

  2006cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

  2006cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• International staging system for multiple myeloma.

  2005influential reference
• Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.

  2003cited by this paper
• Karl Pearson and the Chi-squared Test

  1983cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Individual Comparisons by Ranking Methods

  1945influential reference
• Regression Models and Life-Tables

  year unknowninfluential reference

• Plasma cell development-based prediction of prognosis and treatment response in individual multiple myeloma

  2025cites this paper
• Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical Trials.

  2025cites this paper
• Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines.

  2024cites this paper
• T(11;14) with multiple myeloma: Standard risk survival but slow and poor response

  2024cites this paper
• Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma

  2024cites this paper
• Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs

  2024cites this paper
• Molecular Pathogenesis of Multiple Myeloma: Clinical Implications.

  2024cites this paper
• Still high risk? A review of translocation t(14;16) in multiple myeloma

  2024cites this paper
• Construct prognostic models of multiple myeloma with pathway information incorporated

  2024cites this paper
• Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up

  2023cites this paper
• Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis

  2023cites this paper
• EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression

  2023cites this paper
• Bone metabolism parameters and their relation to cytogenetics in multiple myeloma

  2022cites this paper
• Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.

  2021cites this paper
• Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles

  2021cites this paper
• Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma Myeloma

  2021cites this paper
• Strategies to Overcome High-Risk Multiple Myeloma

  2021cites this paper
• Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019

  2021cites this paper
• Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

  2021cites this paper
• Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials

  2020cites this paper
• What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?

  2020cites this paper
• Cyclin D1 targets hexokinase 2 to control aerobic glycolysis in myeloma cells

  2020cites this paper
• The molecular biology of multiple myeloma

  2019cites this paper
• CD38 negative anaplastic plasma cell myeloma with (14;16) translocation: a diagnostic dilemma for highly aggressive neoplasm: case report

  2019cites this paper
• Unfavourable biological prognostic factors in Multiple Myeloma

  2019cites this paper
• Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.

  2019cites this paper
• Multiple Myeloma: What Do We Do About Immunodeficiency?

  2019cites this paper
• Kinome expression profiling to target new therapeutic avenues in multiple myeloma

  2019cites this paper
• LENALIDOMIDE AND VORINOSTAT MAINTENANCE AFTER AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA-LONG TERM FOLLOW-UP.

  2019cites this paper
• Hematopoietic Cell Transplantation in Patients With Multiple Myeloma

  2019cites this paper
• Retrospective review of the use of high dose cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) for the treatment of multiple myeloma and plasma cell leukemia

  2019cites this paper
• t(14;16)(q32;q23) IGH/MAF

  2019cites this paper
• Risk adapted post-transplant maintenance in multiple myeloma

  2019cites this paper
• The Molecular Biology of Multiple Myeloma

  2019cites this paper
• Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system

  2019cites this paper
• Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma

  2018cites this paper
• Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma

  2018cites this paper
• Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes

  2018cites this paper
• Treatment of t(4;14) and del(17p) in multiple myeloma

  2018cites this paper
• Maintenance and continuous therapy for multiple myeloma

  2018cites this paper
• High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes

  2018cites this paper
• Treatment of Transplant Eligible Patients with Multiple Myeloma

  2018cites this paper
• MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

  2018cites this paper
• The Evolution of Prognostic Factors in Multiple Myeloma

  2017cites this paper
• Cancer Cytogenetics

  2017cites this paper
• Update on the optimal use of bortezomib in the treatment of multiple myeloma

  2017cites this paper
• Stem Cell Transplantation in Multiple Myeloma.

  2017cites this paper
• Recurrent Cytogenetic Abnormalities in Multiple Myeloma.

  2017cites this paper
• Fixed duration vs continuous therapy in multiple myeloma.

  2017cites this paper
• Personalized Therapy for Multiple Myeloma

  2017cites this paper
• Cure-Rate Survival Models and Their Application to Cancer Clinical Trials

  2017cites this paper
• Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.

  2017cites this paper
• European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses

  2017cites this paper
• Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against

  2017cites this paper
• Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.

  2016cites this paper
• Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy—Results of a Case Control Study

  2016cites this paper
• Effect of melphalan 140 mg/m2 vs 200 mg/m2 on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation—a single center experience

  2016cites this paper
• The role of tandem stem cell transplantation for multiple myeloma patients

  2016cites this paper
• MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.

  2016cites this paper
• Advances in understanding prognosis in myeloma

  2016influential citation
• CME Information

  2016cites this paper
• Correction: Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy—Results of a Case Control Study

  2016cites this paper
• Myeloma today: Disease definitions and treatment advances

  2016cites this paper
• Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma

  2016cites this paper
• The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.

  2016cites this paper
• Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

  2016cites this paper
• Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

  2016cites this paper
• Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.

  2016cites this paper
• The Future of Post-Autologous Stem Cell Transplant Therapy for Multiple Myeloma

  2016cites this paper
• Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants

  2016cites this paper
• The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma

  2015cites this paper
• Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma

  2015cites this paper
• Alantolactone induces G1 phase arrest and apoptosis of multiple myeloma cells and overcomes bortezomib resistance

  2015cites this paper
• Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients

  2015cites this paper
• How I treat high-risk myeloma.

  2015cites this paper
• Desenlaces clínicos en hematoncología: diez años de investigaciones en Pubmed

  2015cites this paper
• Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma

  2015cites this paper
• Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

  2015cites this paper
• Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

  2015cites this paper
• Interpretation of cytogenetic results in multiple myeloma for clinical practice

  2015cites this paper
• MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.

  2015cites this paper
• Using a latent class model to refine risk stratification in multiple myeloma

  2015cites this paper
• HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide

  2015cites this paper
• Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols

  2015cites this paper
• Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development

  2015cites this paper
• Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.

  2015cites this paper
• Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway

  2015cites this paper
• Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.

  2015cites this paper
• Counterpoints: Do patients with multiple myeloma need maintenance treatment? No, maintenance treatment should not be used outside clinical trials.

  2015cites this paper
• Survival Analysis of Total Therapy 3 in Newly Diagnosed Multiple Myeloma

  2015influential citation
• The evolving field of post-transplant therapy in multiple myeloma

  2014cites this paper
• Znaczenie bortezomibu w leczeniu szpiczaka plazmocytowego u pacjentów z ryzykiem cytogenetycznym

  2014cites this paper
• Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia

  2014cites this paper
• Pathogenesis of Multiple Myeloma

  2014cites this paper
• The emerging role of carfilzomib combination therapy in the management of multiple myeloma

  2014cites this paper
• European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

  2014cites this paper
• Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma

  2014cites this paper
• Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis

  2014cites this paper
• Profiling Bortezomib Resistance in Multiple Myeloma: Implications in Personalized Pharmacotherapy

  2014cites this paper
• Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

  2014cites this paper